The Canadian Life and Health Insurance Association is asking the Patented Medicine Prices Review Board to include workplace-related factors when it sets maximum prices for medications. In its submission for the PMPRB’s consultation on its draft guidelines, which were released in November, the CLHIA said the life and health insurance industry is very supportive of the […]
The Canadian Life and Health Insurance Association is asking the federal government to develop a strategy for access to high-cost drugs and to make flexible annuity options available for a variety of retirement savings vehicles. In its 2020 budget submission to Finance Minister Bill Morneau, the association called for the federal government to work with provincial and territorial governments and […]
The vast majority of pharmaceutical executives said they expect the incoming amendments to the Patented Medicine Prices Review Board to have a negative impact on their business plans in Canada, according to a new survey commissioned by Life Sciences Ontario. The survey, which drew on data from 46 respondents, including leaders from 36 Canadian and […]
The Canadian Life and Health Insurance Association is highlighting new retirement savings options and access to cheaper drugs in its priorities for the Quebec and Newfoundland and Labrador provincial budgets. In its submission to Newfoundland’s finance minister, the CLHIA called for the government to make pooled registered pension plans available in the province. Citing Statistics Canada data that […]
While insomnia is a disorder, it’s just as commonly a symptom, which most people and physicians don’t grasp, said Dr. Atul Khullar, medical director at the Northern Alberta Sleep Clinic. A lot of times, not sleeping is essentially the body breaking down because of a separate disorder, risk factor or residual symptom of a mental-health […]
On Dec. 3, the 2019 Face to Face Drug Plan Management Forum featured sessions on rare disease, the pharmaceutical industry’s point of view, legal obligations in drug plan management and a deeper dive into drug programs. Capping coverage for plan members with rare diseases poses an ethical dilemma While high-cost specialty medications represent about 30 […]
Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are getting to the right patients, according to Kathy Sotirakos, senior manager of market access and private insurance at Amgen. Real world evidence will help inform better decision-making from a predictability and outcomes perspective, she said during a panel at […]
As the landscape of Canadian drug plan management continues to evolve, several programs are being implemented by insurers and pharmacy benefits managers to help plan sponsors manage costs. Speaking on a panel at Benefits Canada’s 2019 Face to Face Drug Plan Management Forum on Dec. 3 in Toronto, Ned Pojskic, leader of pharmacy and health provider […]
The Patented Medicine Prices Review Board has published draft guidelines, including new factors for setting patented drug prices and an updated list of reference countries for Canada to compare its prices. The guidelines were updated to address the federal government’s final amendments to the PMPRB rules, which were released in August. The board is seeking comment from stakeholders until Jan. 20, […]
Ontario has proposed amendments to provincial drug regulations that aim to change the pricing model for generic drugs and simplify the process for the province’s drug formulary to list biosimilars. Ontario’s Ministry of Health and Long-Term Care said the changes are aimed at reducing the “administrative burden” for drug manufacturers and pharmacies. With regards to […]